Tislelizumab 是一种对 PD-1 受体具有高结合亲和力的单克隆抗体，可最大限度地减少 Fcγ 受体与巨噬细胞的结合，从而消除抗体依赖性吞噬作用，这是一种 T 细胞清除机制，可对抗 PD-1 治疗的潜在耐药性。Tislelizumab 可用于晚期鳞状非小细胞肺癌的研究。
货号:ajcx38780
CAS:1858168-59-8
分子式:N/A
分子量：N/A
溶解度:N/A
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Tislelizumab, a monoclonal antibody with high binding affinity to the PD-1 receptor, minimizes Fcγ receptor binding on macrophages, thereby abrogating antibody-dependent phagocytosis, a mechanism of T cell clearance and potential resistance to anti-PD-1 therapy. Tislelizumab can be used for the research of advanced squamous non-small-cell lung cancer[1].

[1]. Jie Wang, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717.